- Home
- KROS vs ZVRA Comparison
KROS vs ZVRA Comparison
Compare KROS & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- ZVRA
- Stock Information
- Founded
- KROS 2015
- ZVRA 2006
- Country
- KROS United States
- ZVRA United States
- Employees
- KROS N/A
- ZVRA N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- ZVRA Health Care
- Exchange
- KROS Nasdaq
- ZVRA Nasdaq
- Market Cap
- KROS 460.6M
- ZVRA 419.5M
- IPO Year
- KROS 2020
- ZVRA 2015
- Fundamental
- Price
- KROS $11.00
- ZVRA $8.10
- Analyst Decision
- KROS Buy
- ZVRA Strong Buy
- Analyst Count
- KROS 11
- ZVRA 7
- Target Price
- KROS $45.33
- ZVRA $21.20
- AVG Volume (30 Days)
- KROS 2.1M
- ZVRA 436.6K
- Earning Date
- KROS 02-26-2025
- ZVRA 03-27-2025
- Dividend Yield
- KROS N/A
- ZVRA N/A
- EPS Growth
- KROS N/A
- ZVRA N/A
- EPS
- KROS N/A
- ZVRA N/A
- Revenue
- KROS $651,000.00
- ZVRA $24,489,000.00
- Revenue This Year
- KROS $303.27
- ZVRA N/A
- Revenue Next Year
- KROS N/A
- ZVRA $380.11
- P/E Ratio
- KROS N/A
- ZVRA N/A
- Revenue Growth
- KROS 8037.50
- ZVRA 47.85
- 52 Week Low
- KROS $9.78
- ZVRA $4.20
- 52 Week High
- KROS $73.00
- ZVRA $9.76
- Technical
- Relative Strength Index (RSI)
- KROS 24.79
- ZVRA 37.18
- Support Level
- KROS $11.04
- ZVRA $7.73
- Resistance Level
- KROS $11.99
- ZVRA $8.24
- Average True Range (ATR)
- KROS 0.60
- ZVRA 0.32
- MACD
- KROS 1.20
- ZVRA -0.01
- Stochastic Oscillator
- KROS 43.99
- ZVRA 19.53
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.